These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 15324518

  • 1. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S67-73. PubMed ID: 15324518
    [Abstract] [Full Text] [Related]

  • 2. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S59-66. PubMed ID: 15324517
    [Abstract] [Full Text] [Related]

  • 3. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [Abstract] [Full Text] [Related]

  • 4. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Aug; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 6. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
    Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM.
    Circulation; 2005 May 17; 111(19):2446-53. PubMed ID: 15867184
    [Abstract] [Full Text] [Related]

  • 7. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark].
    Palmer AJ, Lammert M, Hermansen K.
    Ugeskr Laeger; 2008 Apr 07; 170(15):1250-4. PubMed ID: 18433583
    [Abstract] [Full Text] [Related]

  • 8. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, Spinas GA.
    Curr Med Res Opin; 2004 Aug 07; 20 Suppl 1():S53-8. PubMed ID: 15324516
    [Abstract] [Full Text] [Related]

  • 9. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.
    Schütt M, Kern W, Krause U, Busch P, Dapp A, Grziwotz R, Mayer I, Rosenbauer J, Wagner C, Zimmermann A, Kerner W, Holl RW, DPV Initiative.
    Exp Clin Endocrinol Diabetes; 2006 Jul 07; 114(7):384-8. PubMed ID: 16915542
    [Abstract] [Full Text] [Related]

  • 10. Validation of the CORE Diabetes Model against epidemiological and clinical studies.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA.
    Curr Med Res Opin; 2004 Aug 07; 20 Suppl 1():S27-40. PubMed ID: 15324514
    [Abstract] [Full Text] [Related]

  • 11. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
    Shichiri M, Kishikawa H, Ohkubo Y, Wake N.
    Diabetes Care; 2000 Apr 07; 23 Suppl 2():B21-9. PubMed ID: 10860187
    [Abstract] [Full Text] [Related]

  • 12. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
    Roze S, Valentine WJ, Evers T, Palmer AJ.
    Curr Med Res Opin; 2006 Jul 07; 22(7):1415-24. PubMed ID: 16834840
    [Abstract] [Full Text] [Related]

  • 13. Lifetime health effects and costs of diabetes treatment.
    Niessen LW, Dijkstra R, Hutubessy R, Rutten GE, Casparie AF.
    Neth J Med; 2003 Nov 07; 61(11):355-64. PubMed ID: 14768718
    [Abstract] [Full Text] [Related]

  • 14. HIS modelling and simulation based cost-benefit analysis of a telemedical system for closed-loop diabetes therapy.
    Bott OJ, Hoffmann I, Bergmann J, Gusew N, Schnell O, Gómez EJ, Hernando ME, Kosche P, von Ahn C, Mattfeld DC, Pretschner DP.
    Int J Med Inform; 2007 Dec 07; 76 Suppl 3():S447-55. PubMed ID: 17656150
    [Abstract] [Full Text] [Related]

  • 15. Intensive insulin therapy in insulin-dependent diabetes mellitus, the results of the diabetes control and complications trial.
    Duron F.
    Biomed Pharmacother; 1995 Dec 07; 49(6):278-82. PubMed ID: 7579008
    [Abstract] [Full Text] [Related]

  • 16. Use of insulin and weight gain: optimizing diabetes nutrition therapy.
    Daly A.
    J Am Diet Assoc; 2007 Aug 07; 107(8):1386-93. PubMed ID: 17659906
    [Abstract] [Full Text] [Related]

  • 17. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov 07; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 18. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr 07; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 19. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV, Frick KD, Wade A, Simko R, Burge R.
    Clin Ther; 2009 Apr 07; 31(4):862-79. PubMed ID: 19446159
    [Abstract] [Full Text] [Related]

  • 20. Technology and the issue of cost/benefit in diabetes.
    Giannini C, Mohn A, Chiarelli F.
    Diabetes Metab Res Rev; 2009 Sep 07; 25 Suppl 1():S34-44. PubMed ID: 19662616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.